Assessment of readability of gynecologic cancer clinical trials literature at National Cancer Institute–designated Comprehensive Cancer Centers
Julia Chalif(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Laura Chambers(Twitter (United States)), John L. Hays(The Ohio State University), Wafa Khadraoui(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Larry J. Copeland(Gynecologic Oncology Group), Roberto Vargas(Gynecologic Oncology Group), David M. O’Malley(The Ohio State University)
Cited by 1
Related Papers
NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
|Journal of the National Comprehensive Cancer Network|2019|332
Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma
|Molecular Cancer Therapeutics|2020|138
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
|Journal of Clinical Oncology|2023|100
Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398
|Molecular Cancer Therapeutics|2017|93